Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NATCO Pharma Limited
NATCOPHARM | NSE
1,055.65
INR-44.40
-4.04%
NATCOPHARM | NSE
Loading StockChartView...
About NATCO Pharma Limited
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
31/03/2024
As of date
21/04/2026
Close
1,055.65
Open
1,100.10
High
1,103.00
Low
1,052.00
NATCO Pharma Limited a pharmaceutical company develops manufactures and markets finished dosage formulations and active pharmaceutical ingredients (APIs). It offers formulations in various therapeutic areas including cancers of blood liver kidney lung brain breast ovary etc.; and APIs in various categories such as oncology central nervous system pain management and CV care. The company also offers orthopedic products comprising bisphosphonates which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C as well as contract manufacturing services. In addition it provides cardiology and diabetology products for the treatment of hypertension stable angina and CHF; and agro chemicals and biological pest management solutions for management of insects diseases and weeds across a range of crops. The company markets its products in approximately 50 countries. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad India.
View LessNATCOPHARM | NSE
Risk
40.0
Sharpe
1.03
Luna's Score
64/100
Recommendation
Hold
Luna says (NATCOPHARM | NSE)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Operating Margin (> 25%)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
Midcap (2B - 10B USD)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
45.7%1 month
40.0%3 months
39.7%6 months
39.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
15.31
Fwd. PE
15.46
Price to book
4.25
Debt to equity
0.06
Debt to assets
0.05
Ent. to EBITDA
12.55
Ent. to rev.
5.90
PEG
-
Other Fundamentals
EBITDA
21.63B
MarketCap
189.08B
MarketCap(USD)
2.02B
Div. yield
0.89
Op. margin
55.83
Erngs. growth
60.40
Rev. growth
19.50
Ret. on equity
25.88
Short ratio
-
Short perc.
-
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
126.85
Range1M
210.45
Range3M
328.80
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.92
Price X volume
903.57M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 12.55 | 24.85 | Cheaper |
| Ent. to Revenue | 5.90 | 11.40 | Cheaper |
| PE Ratio | 15.31 | 51.36 | Cheaper |
| Price to Book | 4.25 | 6.83 | Cheaper |
| Dividend Yield | 0.89 | 0.52 | Leader |
| Std. Deviation (3M) | 39.73 | 42.17 | Par |
| Debt to Equity | 0.06 | 0.35 | Cheaper |
| Debt to Assets | 0.05 | 0.17 | Cheaper |
| Market Cap | 189.08B | 290.82B | Emerging |
